Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Fortis Healthcare...

    Fortis Healthcare shares fall nearly 3 percent

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-05-14T14:07:14+05:30  |  Updated On 14 May 2018 2:07 PM IST
    Fortis Healthcare shares fall nearly 3 percent
    New Delhi: Shares of Fortis Healthcare fell nearly 3 percent today after the company announced that its board has picked the offer from Munjals-Burmans combine over four other suitors who made binding offers.

    The stock declined 2.66 percent to close at Rs 148.40 on BSE. Intra-day, it slumped 4.39 per cent to Rs 145.75.
    At NSE, shares of the company fell 2.27 percent to end at Rs 149.50.

    The companys market valuation fell by Rs 208.78 crore to Rs 7,697.22 crore.

    In terms of equity volume, 11.58 lakh shares of the company were traded on BSE and over one crore shares changed hands at NSE during the day.

    The board of Fortis yesterday recommended the binding offer of the Munjals-Burmans combine to the shareholders after 18 months of hectic parleys with several potential investors for the sale of its business.

    The board decided by majority to recommend the revised offer of Hero Enterprise Investment Office-Burman Family Office made on May 1 for an upfront equity infusion of Rs 800 crore at a price of Rs 167 per share through preferential allotment, Fortis said in a late-night filing to BSE yesterday.

    The Munjals-Burmans combine further agreed to invest another Rs 1,000 crore via preferential issue of warrants priced at Rs 176 per share, it added.

    Read Also: Battle For Fortis: Munjal-Burmans emerge Victorious

    BSEFortis HealthcareHero Enterprise Investment OfficeInvestorsMunjals-BurmansNSE
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok